Alpha Tau Medical (NASDAQ:DRTS) Issues Earnings Results, Misses Estimates By $0.01 EPS

Key Points

• Alpha Tau Medical reported quarterly earnings of ($0.13) EPS, missing analysts' estimates of ($0.12) by ($0.01).
• Despite the earnings miss, Alpha Tau Medical's stock price increased by 5.0%, reaching $3.56 during trading hours.
• HC Wainwright reaffirmed a "buy" rating on the stock with a target price of $9.00.

Alpha Tau Medical (NASDAQ:DRTS - Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.01), Zacks reports.

Alpha Tau Medical Stock Performance

Shares of NASDAQ:DRTS traded up $0.06 on Friday, reaching $3.26. 3,923 shares of the company's stock were exchanged, compared to its average volume of 63,523. The firm has a market capitalization of $276.51 million, a price-to-earnings ratio of -6.79 and a beta of 0.99. Alpha Tau Medical has a fifty-two week low of $2.11 and a fifty-two week high of $4.39. The business's 50-day moving average is $3.09 and its two-hundred day moving average is $2.92. The company has a quick ratio of 5.81, a current ratio of 10.52 and a debt-to-equity ratio of 0.07.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a "buy" rating and issued a $9.00 price objective on shares of Alpha Tau Medical in a research report on Tuesday, April 29th.

About Alpha Tau Medical

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others.